• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Latest

The Forgotten Trend that Could Be Set for a Resurgence…

Like 0

By Ryan Clarkson-Ledward, Friday, 08 July 2022

Amidst the chaos of the past two years, Aussie investors have seen a handful of trends come and go. But the one trend that has been largely forgotten is baby formula...

Amidst the chaos of the past two years, Aussie investors have seen a handful of trends come and go.

‘Buy now, pay later’ (BNPL) stocks are certainly one of the first sectors that come to mind. It’s a trend that went from boom to bust in the span of the pandemic volatility.

Likewise, lithium has emerged as one of the new popular trends to get involved in. And while we have certainly seen a lot of steam come out of the sector, it still has some momentum behind it.

But the one trend that has been largely forgotten is baby formula…

Back in 2018/19, before investors even knew what COVID was, baby formula was a highly prized commodity. Stocks like The a2 Milk Company [ASX:A2M], Bubs Australia [ASX:BUB], and Bellamy’s (before it was taken over) were the cream of the crop.

These kings of market had tapped into the huge Chinese ‘daigou’ market. Essentially, local buyers would snap up local stock and then ship it themselves to China for resale. This process was lucrative due to Chinese parents’ scepticism about the safety of local products.

However, that all changed when the pandemic finally set in…

Supply chain meltdown

As with many industries, COVID wreaked havoc on baby formula supply chains.

Getting products into China was already getting tough pre-pandemic with crackdowns on daigou channels and the trade war, but COVID lockdowns really sealed the deal. The baby formula trade, as lucrative as it had been, was basically dead.

And that’s the way things have remained for a while now.

There seems to be little hope about rekindling the opportunity in the huge Chinese market. That’s precisely why stocks like A2M and BUB have tanked pretty hard.

But, in a somewhat surprising turn of events, a new market has opened up…

The US is now in the midst of a major baby formula crisis.

The leading cause of this shortage is due to ongoing factory closures of key manufacturing facilities.

Most notably, the Abbott plant in Michigan was closed earlier this year due to concerns over safety risks to infants. And while it was recently reopened after being cleared of any concerns, it has since had to close again due to flooding.

As a result, desperate parents are struggling to get a hold of the formula they need. And because of this, it has opened up a window of opportunity for Aussie producers, like Bubs, to fill the gap.

An underdog comeback

See, Bubs in particular has recently managed to secure a pretty meaningful win.

In cooperation for supplying US parents with their formula, the Biden administration has given them the greenlight for a permanent market presence in the US.

That is a huge deal for a market that has been so heavily concentrated for so long. Up until now, just two companies (Abbott and Reckitt Benckiser) have dominated the sector with an 80% market share. After all, the US has been strict about regulating such an important product for infants.

Now, though, with Bubs securing this agreement, they have a chance to carve out their own niche.

As FDA commissioner Robert Califf notes on the matter:

‘These flexibilities have been successful in helping to bring safe and nutritionally adequate infant formula products into the US marketplace on a temporary basis to address the formula shortage.

‘Given that success, the FDA has determined that a more streamlined pathway that leverages information we have received for the products for which we are temporarily exercising enforcement discretion would help provide for the long-term availability and marketing of many of them.’

For local manufacturers that have relied on Chinese demand for so long, this pivot from the FDA could be their saving grace. Like I said, Bubs is already paving the way on this front, but don’t be surprised if others try to follow in their footsteps.

Shareholders will no doubt be excited about this news, especially long-term holders.

But, for investors in general, this story should serve as a reminder as to how quickly trends can change.

All it takes is one breakthrough, or one slight opportunity, to revive a seemingly dead trade.

Regards,


Ryan Clarkson-Ledward Signature

Ryan Clarkson-Ledward,
Editor, Money Morning

Ryan is also co-editor of Exponential Stock Investor, a stock tipping newsletter that hunts down promising small-cap stocks. For information on how to subscribe and see what Ryan’s telling subscribers right now, click here.

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Ryan Clarkson-Ledward

Ryan’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • OpenAI and Microsoft Divorce?: Why this could be good for you
    By Charlie Ormond

    While breakups are rarely pretty, this one might actually benefit investors willing to look beyond the drama.

  • Three Lithium Stocks in the Buy Zone
    By Murray Dawes

    Lithium stocks jumped this week, so Murray and Callum discuss whether this could be the beginning of the second boom in lithium stocks. They also discuss a fund manager that is recovering and looking cheap

  • Every Australian Investor Has a Stake in Mining
    By James Cooper

    With its deep pool of retirement capital, Australia is on track to become the world’s primary destination for resource markets.

Primary Sidebar

Latest Articles

  • OpenAI and Microsoft Divorce?: Why this could be good for you
  • Three Lithium Stocks in the Buy Zone
  • Every Australian Investor Has a Stake in Mining
  • The next wave of AI winners
  • Could the US People Repudiate the National Debt?

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988